Kodiak Sciences, Wet AMD, and the Biotech Catalyst Every Trader Wants
Updated: Oct 6
As someone who trades the market daily, you can't help but feel a little envy when you watch a stock like Kodiak Sciences (KOD) explode higher in a single session.
Not because the move looks easy. It wasn’t.
Biotechnology is one of the hardest corners of the market to trade because companies can spend years burning capital, conducting trials, missing endpoints, redesigning programs, and waiting for regulators before one morning changes the entire valuation.
Kodiak Sciences just had one of those mornings.
On September 28, 2026, Kodiak announced that both Zenkuda, or tarcocimab tedromer, and tabirafusp-ted met the primary endpoint in the Phase 3 DAYBREAK trial for wet age-related macular degeneration. Both investigational therapies achieved noninferior vision gains compared with aflibercept at one year. Zenkuda also demonstrated extended durability, with 54% of patients reaching a 24-week dosing interval under the study’s retreatment criteria.
For a clinical-stage biotechnology company, that is the kind of catalyst traders wait for.
For patients, the story begins somewhere much smaller. At the back of the eye.
Why Wet AMD Matters
The retina is a thin layer of neurosensory tissue lining the back of the eye. Its job sounds simple: capture light and convert it into neural signals that the brain interprets as images.
The biology behind that process is anything but simple.
At the center of the retina sits the macula, the region responsible for detailed central vision. Within the macula lies a dense population of photoreceptors, including cones that allow us to read, recognize faces, distinguish fine detail, and see what is directly in front of us. When the macula fails, peripheral vision may remain intact. But the center of the visual world can disappear.
Wet AMD, also called neovascular or exudative AMD, represents an advanced form of the disease. It develops when abnormal blood vessels form beneath or within the retina and begin leaking fluid or blood. Vascular endothelial growth factor, or VEGF, drives much of this abnormal blood-vessel growth.
Clinically, this process is known as choroidal neovascularization, or CNV.
Abnormal vessels grow from the choroidal circulation beneath the retina, often extending through structures that normally separate these tissues, including Bruch’s membrane and the retinal pigment epithelium.
These vessels are fragile. They leak. They bleed. They distort retinal anatomy. And the macula pays the price.
Without treatment, wet AMD can cause rapid and irreversible central vision loss. The patient may retain peripheral vision, but reading a medication bottle, seeing a spouse's face, driving, writing a check, or navigating a familiar room can become difficult or impossible.
This is not a trivial loss of vision. It is a loss of independence.
VEGF Changed the Disease
Before anti-VEGF therapy, clinicians had limited ability to prevent severe visual loss from neovascular AMD. Then VEGF became a therapeutic target.
VEGF promotes abnormal vascular growth and leakage in the retina. Anti-VEGF medications interfere with that process, suppressing the growth and permeability of these vessels.
Doctors administer the medications directly into the eye's vitreous cavity through an intravitreal injection. That sounds dramatic. In retinal medicine, it's routine.
Regular anti-VEGF treatment has transformed wet AMD from a disease that once commonly progressed toward severe central visual loss into one that clinicians can often control for years.
But control comes with a price. Repeated treatment. Treatment may begin with injections spaced only weeks apart. Clinicians then adjust the interval based on retinal imaging, fluid, vision, disease activity, and the patient’s individual response.
For some patients, this becomes a long-term cycle:
Appointment.
Imaging.
Injection.
Return.
Repeat.
Now consider the population most affected by wet AMD. Older adults.
Some no longer drive.
Some depend on family for transportation.
Some have multiple chronic conditions.
Some receive injections in both eyes.
Some miss appointments.
Some simply become exhausted by the burden of maintaining treatment.
This is where the clinical and commercial importance of durability becomes obvious.
The question is no longer simply: Can the drug preserve vision?
It is also: How long can the drug preserve control before the patient needs another injection?
Enter Kodiak Sciences
Kodiak Sciences is a precommercial biotechnology company focused on retinal diseases. Its pipeline centers on therapies designed to preserve the efficacy of retinal biologics while extending their duration inside the eye. That is an ambitious target. Existing anti-VEGF therapies already work.
Kodiak must therefore offer something beyond simply working.
It has to compete on durability, retinal drying, dosing burden, safety, or some combination of all four. Zenkuda is Kodiak’s lead investigational therapy.
The drug uses the company’s antibody-biopolymer conjugate platform, designed to extend how long an active therapeutic agent remains in the eye. Tabirafusp-ted takes the concept further by targeting both VEGF and interleukin-6, or IL-6, potentially addressing inflammatory biology in addition to abnormal vascular growth.
Then came DAYBREAK.
What Happened in the DAYBREAK Trial
DAYBREAK is a Phase 3 study evaluating Zenkuda and tabirafusp-ted against aflibercept in treatment-naïve patients with wet AMD.
On September 28, 2026, Kodiak announced that both investigational therapies met their primary endpoint, demonstrating noninferior gains in best-corrected visual acuity compared with aflibercept at one year. That alone mattered. But durability drove much of the excitement.
Kodiak reported that 54% of patients treated with Zenkuda reached a 24-week dosing interval at year one while using strict retreatment criteria based on maintaining a dry retina.
Twenty-four weeks. About six months. For a disease that often requires repeated intravitreal injections, that number gets attention.
Clinically. Commercially. And on Wall Street.
Kodiak also reported that Zenkuda produced vision outcomes comparable to aflibercept through one year and showed rapid retinal drying during the loading phase. Tabirafusp-ted met both its visual-acuity primary endpoint and an anatomical secondary endpoint.
These remain topline company-reported results, and detailed peer-reviewed data will matter.
But the market did not wait for the journal article. It rarely does.
Why the Stock Exploded
Clinical-stage biotechnology companies live differently from mature businesses.
There may be little or no commercial revenue. No established product franchise. No decades of predictable cash flow. Instead, valuation often rests on probability.
Will the drug work?
Will it fail?
Will the safety profile hold?
Will regulators accept the data?
Will physicians use it?
Will insurers pay for it?
Until a major readout arrives, investors are pricing uncertainty. Then Phase 3 data hit. Suddenly the probability tree changes. That is what happened with Kodiak. The biology did not transform overnight. Investor knowledge about the biology did.
That difference can add or remove billions of dollars in market value in a single trading session.
The Catalyst Every Trader Wants
Anyone who trades daily knows the feeling. You look at a biotech chart after the catalyst. The stock is up 80%. Then 100%. Then more.
And one thought inevitably appears: How did I miss that?
But the chart after the announcement hides what it looked like before. Before the data, the outcome was uncertain. A positive Phase 3 trial can transform a company. A failed trial can destroy one. The exact characteristic that creates extraordinary upside also creates extraordinary downside.
That is what makes biotech trading so seductive. And so unforgiving.
Everyone wants the candle after the press release. Very few people want the binary risk the night before it.
Kodiak Is Not Finished
Positive Phase 3 results do not equal FDA approval. Kodiak says it plans to submit a multi-indication Biologics License Application for Zenkuda in the fourth quarter of 2026, supported by five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion. That creates the next set of catalysts.
Regulatory submission.
FDA acceptance.
Review.
Potential approval.
Labeling.
Manufacturing.
Pricing.
Reimbursement.
Commercial uptake.
Competition.
And eventually real-world evidence.
Kodiak still has to move from proving that a drug can work in a clinical trial to proving that physicians, patients, payers, and health systems want to use it.
Those are different tests.
Competition Will Not Stand Still
Aflibercept is already deeply established in retinal medicine. Other anti-VEGF therapies have years of clinical experience behind them. Kodiak therefore enters a market where physicians already have drugs they know how to use. That matters.
Noninferiority alone does not guarantee commercial success. Kodiak will need to demonstrate why a clinician should change treatment behavior. Durability may be that reason. If a therapy can deliver comparable visual outcomes while meaningfully reducing injection frequency, the benefit is easy to understand.
Fewer procedures.
Fewer clinic visits.
Less transportation burden.
Potentially better adherence.
And less opportunity for disease recurrence between missed treatments.
But controlled clinical trials are not ordinary life. Patients miss appointments. Insurance changes. Comorbidities interfere. Some patients clear drugs faster than others.
Disease activity varies. The real test comes after approval.
The Patient Behind the Ticker
This is the part traders can forget. KOD is a ticker. Wet AMD is not.
Behind every retinal trial is someone trying to preserve the ability to see the center of the world in front of them.
That makes biotechnology different from many other sectors.
A semiconductor company may make computing faster.
A retailer may improve margins.
A biotechnology company may spend a decade trying to keep someone from losing their sight.
Success can generate extraordinary market value. Failure can erase it. But neither outcome changes the fact that the market reaction begins with a biological question:
Can this molecule alter the course of disease?
For Kodiak, the latest answer appears increasingly encouraging. But the story is not complete.
Where Medicine and the Market Meet
Kodiak Sciences offers a nearly perfect example of why biotechnology fascinates me as both a clinician and someone who watches markets every day.
The science is difficult.
The timelines are long.
The capital requirements are enormous.
And sometimes years of work come down to a handful of endpoints released before the opening bell.
On September 28, Kodiak gave investors what every clinical-stage biotechnology company eventually needs: Data that can change the probability of success. Both DAYBREAK candidates met their primary endpoint.
Zenkuda demonstrated the possibility of six-month dosing in more than half of patients under the study’s retreatment criteria. And Kodiak moved closer to asking regulators whether those findings warrant bringing the therapy into clinical practice.
The stock chart tells you what investors thought about the news. Wet AMD explains why the news mattered. Because behind the ticker sits a retina. Behind the retina sits a macula.
And behind the macula is a person trying to keep seeing the world in front of them.
Author: R.E. Hengsterman, MSN, MA, M.E., RN
Registered nurse, night-shift administrator, and author of The Shift Worker’s Paradox
For educational purposes only. Not medical advice.
Editorial Standards
This article follows NurseWhoWrites editorial guidelines emphasizing evidence-based practice, transparent sourcing, and real-world clinical experience.
Comments